Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

9.55
-0.1100-1.14%
Pre-market: 9.50-0.0508-0.53%09:05 EDT
Volume:2.50M
Turnover:24.02M
Market Cap:2.44B
PE:-6.34
High:9.91
Open:9.72
Low:9.48
Close:9.66
52wk High:11.22
52wk Low:6.00
Shares:255.54M
Float Shares:222.00M
Volume Ratio:0.94
T/O Rate:1.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5054
EPS(LYR):1.21
ROE:587.33%
ROA:52.86%
PB:-5.37
PE(LYR):7.89

Loading ...

Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and BioCryst (BCRX)

TIPRANKS
·
Apr 16

BioCryst to report first-quarter financial results, host conference call and webcast

Reuters
·
Apr 15

A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New R&D Leadership Appointment

Simply Wall St.
·
Apr 09

BioCryst files Form 3 for Chief R&D Officer Sandeep Menon

Reuters
·
Apr 08

BioCryst names Sandeep Menon chief research and development officer

Reuters
·
Apr 06

Press Release: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

Dow Jones
·
Apr 06

BioCryst grants inducement equity awards to 12 new hires under Nasdaq rule 5635(c)(4)

Reuters
·
Apr 03

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 03

BioCryst Shares Remain Undervalued, RBC Says

MT Newswires Live
·
Mar 25

RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)

TIPRANKS
·
Mar 25

BioCryst director Theresa Heggie disposes of USD 504,000 in common shares

Reuters
·
Mar 25

BioCryst Chief Legal Officer Alane P. Barnes disposes of USD 1.37 million in common shares

Reuters
·
Mar 19

Is It Time To Reconsider BioCryst Pharmaceuticals (BCRX) After Recent Share Price Strength

Simply Wall St.
·
Mar 18

BioCryst grants 65,850 RSUs to six new hires under Nasdaq inducement rule

Reuters
·
Mar 04

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Mar 04

BioCryst price target raised to $22 from $21 at Wedbush

TIPRANKS
·
Mar 02

Brand Risks Emerge in BioCryst’s ORLADEYO Sale to Neopharmed as Fragmented Positioning Threatens Long‑Term Value

TIPRANKS
·
Feb 28

BioCryst Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 28

Wedbush Adjusts Price Target on BioCryst Pharmaceuticals to $22 From $21, Maintains Outperform Rating

MT Newswires Live
·
Feb 28

Stock Track | Biocryst Pharmaceuticals Soars 5.06% Intraday on Positive Analyst Rating

Stock Track
·
Feb 27